Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTTO: Lapatinib and Trastuzumab in Adjuvant HER2+ Breast Cancer
NCT00490139Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2007
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 44
01
Overview
Phase 3, randomised, open-label trial of lapatinib in breast cancer (4 arms), sponsored by Novartis. Primary endpoint: Disease-Free Survival at 4.5 years. Started May 2007; status: completed.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00490139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00490139.